Table 1.
Demographic and clinical characteristics of lung transplant recipients (LTRs).
| Participant Characteristics | LTRs (n = 49) |
|---|---|
| Age, years (median ± IQR) | 64 (60.5–68) |
| Female sex, n (%) | 24 (48.9) |
| White, n (%) | 47 (95.9) |
| Non-white, n (%) | 2 (4.1) |
| Initial respiratory disease, n (%) | |
| Chronic obstructive pulmonary disease | 34 (69.4) |
| Pulmonary fibrosis | 7 (14.3) |
| Other | 8 (16.3) |
| Types of lung transplantation | |
| Bi-pulmonary transplantation | 47 (95.9) |
| Mono-pulmonary transplantation | 2 (4.1) |
| Years since transplant, years (median ± IQR) | 3.8 (1.8–6.1) |
| Immunosuppressive regimen | |
| Corticosteroids (methylprednisolone), n (%) | |
| 2–6 mg/day | 41 (83.7) |
| ≥8 mg/day | 8 (16.3) |
| Calcineurin inhibitors, n (%) | |
| Tacrolimus | 43 (87.7) |
| Cyclosporine | 6 (12.2) |
| Others, n (%) | |
| Mycophenolate mofetil | 25 (51.0) |
| Azathioprine | 11 (22.4) |
| Everolimus | 8 (16.3) |
| Type of vaccines, n (%) | |
| Two-dose ChAdOx1 nCoV-19 vaccine | 49 (100) |
| BNT162b2 mRNA COVID-19 vaccine (3rd dose) | 32 (65.3) |
IQR, interquartile range.